A dose‐ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty

Prevention of Venous Thromboembolism

William Geerts, John A. Heit, Charles Marc Samama · CHEST Journal · 2008 · 3.8K citations

Medicine, Hematology, Preventive Medicine +11

Effect of antihemophilic factor on one-stage clotting tests; a presumptive test for hemophilia and a simple one-stage antihemophilic factor assy procedure.

R. D. Langdell, Robert H. Wagner, K. M. Brinkhous · PubMed · 1953 · 742 citations

Medicine, Hematology, Hemostasis +9

Clinical Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Factor Xa Inhibitor Edoxaban in Healthy Volunteers

Koichiro Ogata, Jeanne Mendell‐Harary, Masaya Tachibana et al. · The Journal of Clinical Pharmacology · 2010 · 448 citations

Pharmacy, Pharmacokinetics, Pharmacology +13

The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement

Michael R. Lassen, Bruce L. Davidson, Alexander Gallus et al. · Journal of Thrombosis and Haemostasis · 2007 · 370 citations

Medicine, Orthopaedic Surgery, Orthopedic Surgery +14

A Once-Daily, Oral, Direct Factor Xa Inhibitor, Rivaroxaban (BAY 59-7939), for Thromboprophylaxis After Total Hip Replacement

Bengt I. Eriksson, Lars C. Borris, Ola E. Dahl et al. · Circulation · 2006 · 332 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17